Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
102 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Robert Shalwitz, MD; Invirsa Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal